ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3ᵐᵘᵗ AML

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

Leukemia

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Am J Hematol

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

doi: 10.1002/ajh.70142

Leukemia

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Am J Hematol

Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E, Trigo F, Colorado M, Del Bernal Del Castillo T, Barragan E, Tormo M, Rodríguez Arbolí E, Serrano López J, García Boyero R, Castaño T, Herrera Puente P, Romero Riquelme MA, Sayas Lloris MJ, Algarra-Algarra L, Rodriguez-Medina C, Sossa Melo CL, Labrador Gomez J, Vives S, Salamero O, Amigo ML, Valero Nuñez M, Rojas C, Bass F, García-Fortes M, Vidriales Vicente B, Polo M, Benavente C, Madrigal MD, Espinoza M, Pérez-Encinas M, Amador Barciela ML, Bautista G, Solana-Altabella A, Cano-Ferri I, Colmenares R, García-Ramírez P, Ibáñez Alis F, Barrios García M, Rodríguez-Macías G, López M, Oliva Hernández AY, Cerveró CJ, Martínez-Cuadrón D, Chorão P, Bergua Burgues JM, Montesinos P

doi: 10.1002/ajh.70340

Myelodysplastic syndromes

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

Br J Haematol

Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Čermák J, Langemeijer S, Hellström-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L, EUMDS registry

doi: 10.1111/bjh.70384

Leukemia

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Ye Y, Labopin M, Yakoub-Agha I, Socié G, Blaise D, Gedde-Dahl T, Blau IW, Raiola AM, Byrne J, Daguindau E, Labussière-Wallet H, Huynh A, Bazarbachi A, Nagler A, Brissot E, Li L, Luo Y, Shi J, Mohty M, Huang H, Ciceri F

doi: 10.1002/ajh.70008

Leukemia

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

Leukemia

Smallbone P, Cao K, Saliba RM, Carmarzzi Y, Al-Atrash G, Alvarez M, Rondon G, Fingrut WB, Aljawai YM, Olson AL, Alousi AM, Chen GL, Tanner MR, Zou J, Ramdial JL, Champlin RE, Shpall EJ, Oran B

doi: 10.1038/s41375-026-02907-4

Genitourinary Cancer

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Eur J Cancer

Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ

doi: 10.1016/j.ejca.2025.116110

Myelodysplastic syndromes

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients

Br J Haematol

Bouchla A, Papageorgiou SG, Kotsianidis I, Diamantopoulos P, Gavriilaki E, Bouronikou E, Symeonidis A, Zikos P, Cetiner M, Vlachaki E, Kostourou A, Galanopoulos A, Hatzimichael E, Vervesou EC, Bozdağ SC, Viniou NA, Christoulas D, Dellatola M, Papaioannou M, Papoutselis M, Vlachopoulou D, Syrigou A, Mainou M, Chatzileontiadou S, Pappa V

doi: 10.1111/bjh.20102

Leukemia

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Blood Cancer J

Alsugair A, Gauto Mariotti E, Alhousani MM, Fathima S, Yousuf M, Bolarinwa A, Foran J, Mangaonkar AA, Litzow M, Murthy H, Sproat L, Palmer J, Matin A, Ayala E, Slack J, Porrata L, Iqbal M, Khera N, Punwani N, Kenderian S, Chhabra S, Hogan WJ, Shah MV, Alkhateeb HB, Gangat N, Patnaik M, Tefferi A

doi: 10.1038/s41408-025-01359-w

Oncology · Hematology

ADMIRAL/COMMODORE: A lower risk of relapse or death with gilteritinib maintenance post-HSCT in patients with R/R FLT3^mut AML

Related content

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patients

Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM